Innovative therapies are favored, pharmaceutical companies are constantly "buying, buying and buying"

ReLive Biotechnologies Ltd.
(ReLive or the "Company") announced that it has formally signed an agreement to fully acquire the major assets of Co.
Don AG, a German listed company, and the acquisition is expected to be completed
in November 2022 。 It is reported that in this transaction, ReLive will acquire all the core assets of Co.
Don AG through its German subsidiary, including global intellectual property rights related to Spherox, two internationally leading GMP-level production workshops and related quality control systems.
According to public information, ReLive is a tissue engineering and regenerative medicine company, committed to focusing on the repair and reconstruction
of tissues and organs 。 Since its establishment, ReLive has established R&D, clinical and CMC teams in Boston, USA, and Nanjing and Beijing, China, and has introduced a strategic and scientific advisory board
composed of the world's top scholars, clinical experts and business leaders in tissue engineering and regenerative medicine.
Co.
Don AG is a German biotechnology company
dedicated to the development, production and sale of tissue engineering and regenerative medicine products.
Its core product Spherox is a cell therapy product officially approved for joint cartilage repair and regeneration in Europe (including the European Union, the United Kingdom, Switzerland and other countries), and it is also one of
only two cartilage repair and regeneration products in the world that has been officially approved by European and American regulators on the same name as the flagship product MACI® of Vericel Corporation (NASDAQ: VCEL).
In fact, in recent years, multinational pharmaceutical companies have been making frequent acquisitions of innovative therapies
.
For example, on October 3, Alexion Pharmaceuticals, a subsidiary of AstraZeneca's rare disease business, announced the acquisition of LogicBio Therapeutics
, a clinical-stage genetic company, for $68 million.
Founded in 2014, LogicBio is a clinical-stage genomic drug company treating various genetic diseases including rare diseases, and is currently focusing on developing novel gene therapies
for pediatric patients with rare diseases.
Through this acquisition, AstraZeneca will further accelerate Alexion's rapid development in the field of genomic drugs through the accumulation of technology accumulation in genomics technology platform developed by LogicBio, rare disease R&D team and preclinical development
.
On August 8, Pfizer announced a definitive agreement with biopharmaceutical company Global Blood Therapeutics (GBT) to acquire all outstanding shares of GBT for $68.
50 per share in cash, with a total enterprise value of approximately $5.
4 billion, including debt and net cash from the acquisition
.
The industry believes that the acquisition is due to Pfizer's eyeing of the company's sickle cell disease drug Oxbryta
.
Sickle cell disease affects more than 3 million people worldwide and causes chronic pain, organ failure and early death
.
In the United States, about 17,000 children ages 4 to 11 have SCD, which is particularly common
in African-American groups.
On August 4, Amgen and ChemoCentryx jointly announced that the two companies had reached an agreement to acquire ChemoCentryx
for approximately $3.
7 billion.
The acquisition gave Amgen access to Tavneos (avacopan), a "first-in-class" drug
for patients with severe autoimmune diseases.
According to incomplete statistics, in the first half of 2022, the valuation of M&A transactions in the pharmaceutical industry has reached 61.
7 billion US dollars, with more than 130 transaction
volumes.
On the whole, the M&A transactions of pharmaceutical companies are mainly to expand the scope and strength of the company's business, expand the pharmaceutical pipeline and technology, and increase the company's performance and internationalization
.
Among them, multinational pharmaceutical companies are mostly to reduce the impact
of the patent cliff on future company performance.
According to the current revenue of most multinational pharmaceutical companies, they have enough cash to support the continuous "buying, buying and buying"
.
Therefore, analysts believe that in the market environment where the overall valuation of innovative drugs is declining, it will bring more acquisition opportunities
to multinational pharmaceutical companies.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.